Proton Pump Inhibitors News

Related Pharmaceuticals Industry News

• July 2022: The drug pricing regulator NPPA in India fixed the retail prices for 84 drug formulations, including those used for the treatment of diabetes, headaches, and high blood pressure. As per the order, a single tablet of (SR) Metformin Hydrochloride is expected to be priced at INR 10.47 (USD 0.13), excluding GST.
• July 2022: Glenmark Pharmaceuticals Limited launched sitagliptin and its Fixed Dose Combinations (FDCs) with metformin and other anti-diabetic drugs at an affordable price for adults with type-2 diabetes in India. Each of these brands will have two different variants: SITAZIT M will have sitagliptin (50 mg) + metformin (500 mg/1000 mg); SITAZIT M ER will have sitagliptin (100 mg) + metformin SR (500 mg/1000 mg).

• November 2023: Eli Lilly's Zepbound was approved by the Food and Drug Administration on Wednesday as a potent new weight-loss medication. This clearance allows adults who are overweight or have obesity, along with at least one associated health condition, to benefit from this treatment.
• March 2023: Novo Nordisk A/S, the marketing authorization holder for Wegovy, received a favorable recommendation from the Committee for Medicinal Products for Human Use (CHMP) regarding a modification to the terms of the product's marketing authorization.

• In December 2021, Drug firm Morepen Laboratories received approval from the United States health regulator to market its generic anti-allergy drug (Fexofenadine Hydrochloride) in the American market.
• In March 2021, Valeo Pharma Inc. entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two asthma therapies, Enerzair Breezhaler, glycopyrronium, and mometasone furoate and Atectura Breezhaler.

• November 2023: Eli Lilly, a pharmaceutical company, has received approval from the Food and Drug Administration for their latest weight loss medication called Zepbound. Clinical trials have demonstrated that this drug can assist individuals in shedding up to 52 pounds within a span of 16 months.
• July 2023: The limited availability of Saxenda, Novo Nordisk's weight-loss drug, has been disclosed by the U.S. Food and Drug Administration. This scarcity is a result of the overwhelming demand from patients who are unable to acquire Wegovy, Ozempic, or Mounjaro. This situation arises as Saxenda was the precursor to the highly successful release of Wegovy.

• May 2023: Scilex Holding Company, a Sorrento Company, initiated Phase 2, a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) in subjects with acute low back pain.
• February 2023: Aurobindo Pharma Limited and its subsidiary Aurolife Pharma LLC received final approval from the United States Food & Drug Administration (FDA) to manufacture and market Diclofenac Sodium Topical Solution USP, 2% w/w, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Pennsaid Topical Solution, 2% w/w.

• July 2022: Infinitus, a Chinese herbal health products and services provider, launched a new series of Li Mai Jian supplements with the theme "Making Bones Stronger for Joint Health."
• March 2022: Bioiberica, a global life science company, partnered with ByHealth, a leading Chinese vitamin and dietary supplement supplier, to develop a new product for its market-leading joint health brand, Highflex. Highflex type II collagen tablets meet unmet consumer needs for innovative, low-dose joint health solutions in China.

• January 2023: An Indian company, Alkem, launched its new antibiotic drug against multiple drug-resistant infections in the country. The company's product, Zidavi, is a novel combination of ceftazidime & avibactam and is indicated for various ailments like complicated urinary tract infections.
• May 2023: The United Kingdom government announced up to GBP 39 million (USD 50.11 million) cash for antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF).

• September 2022: Axsome Therapeutics, Inc. initiated a multi-center randomized study to assess the efficiency and safety of AXS-05 (dextromethorphan-bupropion) in comparison with a placebo for the treatment of agitation linked with Alzheimer's disease.
• August 2022: The Food Drug and Administration (FDA) approved Axsome Therapeutics' Auvelity (dextromethorphan-bupropion) extended-release tablets for treating major depressive disorder (MDD) in adults.

Pharmaceutical Cartridges Market News

• In January 2023, West Pharmaceutical Services, Inc. announced its participation in Pharma Pack Europe 2023 held in Paris, France in order to demonstrate its expertise and advancements in packaging & containment. The company developed its innovation for patients as well as clients across the globe with the launch of three new products: West Pack with Corning Valor RTU Vials utilizing Stevanato Group's EZ-fill SG EZ-fill technology, Daikyo Crystal Zenith a FluroTec 5-10mL Cartridge Plunger and 2.25mL Insert Needle Syringe System.
• In September 2022, SCHOTT Pharma expanded its pharmaceutical cartridge production in Hungary and China. The investment by the company in double-digit millions is designed to significantly enhance both countries' production capacities for pharmaceutical cartridges.

• In January 2023, Eisai Co., Ltd., and Biogen Inc. received the European Medicines Agency (EMA) marketing authorization application (MAA) for lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of early Alzheimer's disease.
• In January 2023, Regeneron Pharmaceuticals, Inc., and Sanofi S.A. received the EMA expanded approval of Dupixent (dupilumab), to treat severe atopic dermatitis in children 6 months to 5 years old.